---
title: "Vertex Pharmaceuticals 股票是百万富翁制造者吗？"
description: "Vertex Pharmaceuticals 是一家业务不断增长的公司，拥有强大的囊性纤维化业务。它有多个增长机会，包括一种非阿片类疼痛药物和对 Alpine 免疫科学公司的收购。虽然它的估值很高，但仍可能是一个具有适度预期的良好长期投资。然而，要实现 40 倍回报成为百万富翁是不太可能的"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/202339630.md"
published_at: "2024-04-19T08:32:38.000Z"
---

# Vertex Pharmaceuticals 股票是百万富翁制造者吗？

> Vertex Pharmaceuticals 是一家业务不断增长的公司，拥有强大的囊性纤维化业务。它有多个增长机会，包括一种非阿片类疼痛药物和对 Alpine 免疫科学公司的收购。虽然它的估值很高，但仍可能是一个具有适度预期的良好长期投资。然而，要实现 40 倍回报成为百万富翁是不太可能的

**Vertex Pharmaceuticals** (VRTX 0.10%) is a growing pharmaceutical company with a robust cystic fibrosis (CF) business that generated nearly $10 billion in revenue last year. While there is still more room for the business to get bigger, Vertex is already at a sizable market cap of $100 billion. Does this stock have enough runway to generate significant returns and help you become a millionaire in the long run?

## By expanding its scope, Vertex also increases its upside

Vertex is more than just a CF company, and that's why many growth investors remain bullish on its prospects -- they know there are more growth catalysts out there. Vertex's growth opportunities take the company down multiple avenues, including a non-opioid pain medication that has shown promise in clinical trials.

VX-548 is a non-opioid treatment for pain which could be a game changer for the healthcare industry, giving patients a way to address pain with much less fear of getting addicted to opioids. The company plans to apply for regulatory approval this year. At its peak, VX-548 may generate $5 billion in annual revenue for Vertex.

This month, Vertex also announced plans for its largest acquisition: A $4.9 billion cash purchase of **Alpine Immune Sciences**. It's a clinical-stage company that generates revenue primarily from collaborations. What's appealing to Vertex is the prospect of a treatment for IgA nephropathy, a chronic kidney condition. Alpine's drug for that condition, povetacicept, has been progressing and may begin late-stage trials later this year. It offers Vertex a way to strengthen and further diversify its portfolio.

Earlier this year, Vertex also received positive news about a gene therapy it has been developing with **CRISPR Therapeutics** -- Casgevy. The U.S. Food and Drug Administration approved Casgevy as a treatment for transfusion-dependent beta thalassemia. Late last year, the treatment was also approved for sickle cell disease.

These developments and new products can help strengthen Vertex's growth potential. This year, the company anticipates that its product revenue will total between $10.55 billion and $10.75 billion, rising by a relatively modest 8% at the midpoint. In 2023, its growth rate was 11%.

## Does Vertex's high valuation make it too late to invest in the stock to earn a big return?

Vertex's stock currently trades at 29 times its trailing earnings. That's not a steep multiple for a good growth stock, and it's even cheap compared to the healthcare industry, where the average earnings multiple for the **Health Care Select Sector SPDR Fund** is 32. There's little doubt that Vertex can still be a good investment at its current price, but the big question is whether it can generate the type of returns you would need to make you a millionaire.

I think it's fair to assume most investors are not going to be investing six figures into a stock. Even $50,000 might be a bit rich to put into one investment. Let's assume that you're planning to invest around $25,000. That's a significant enough amount when you have confidence in the business and its operations. Vertex, after all, has a highly profitable business -- it generates profit margins in excess of 35%. At the same time, it has some solid growth prospects. This is the type of stock where a large investment may be justifiable.

But for a $25,000 investment to grow to $1 million, you'd need Vertex's stock to be a 40-bagger. That's a tall task for any company, especially one that's already at a market cap of $100 billion. If Vertex were to grow to 40 times its valuation, you would have to assume that it would blow by $1 trillion and eventually become a $4 trillion stock.

No stock in the world has a valuation that high today. In 20 or 30 years, higher valuations are likely to be more common. But even then, you would need to assume that Vertex will be among the most valuable companies in the world. It's a bit of a stretch, to say the least.

While the company is growing, it doesn't possess an asset that suggests it is going to transform the healthcare industry and generate significant profit and revenue growth for the business for years to come. That's why the odds of this being a millionaire-making investment look low -- unless you invest a whole lot more money.

## Vertex Pharmaceuticals can be a good buy if you temper your expectations

As long as you aren't setting your expectations too high for Vertex, given its modest valuation and increasingly diverse portfolio of assets, this can make for an excellent long-term investment. It may not be able to replicate the 500%-plus returns it has generated over the past 10 years, but there's still room to make a great return from Vertex in the long run.

### Related Stocks

- [VERX.US - Vertex](https://longbridge.com/zh-CN/quote/VERX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Vertex｜8-K：2025 财年营收 7.48 亿美元超过预期 |  | [Link](https://longbridge.com/zh-CN/news/275603937.md) |
| 当 “飞机发动机” 成为 “数据中心供电” 标的 | 随着 AI 数据中心对电力需求的指数级增长，传统电网扩容的滞后已成为行业公敌。这一背景下，FTAI Aviation、ProEnergy 等公司正加速将航空动力资产 “降维” 引入电力市场。 | [Link](https://longbridge.com/zh-CN/news/276216835.md) |
| 谷歌突然发布 Gemini 3.1 Pro：核心推理性能直接翻倍 | 谷歌发布了最新的大模型 Gemini 3.1 Pro，其推理性能较去年发布的 Gemini 3 Pro 翻倍。在 ARC-AGI-2 评测中，Gemini 3.1 Pro 得分 77.1%，显示出强大的推理能力。新模型支持多源数据综合和复杂 | [Link](https://longbridge.com/zh-CN/news/276396515.md) |
| “大空头” 预言又一次 “DeepSeek 冲击” | “大空头” Michael Burry 转发关于 DeepSeek 新一代大模型的分析，认为其低成本创新架构将冲击美股数据中心交易热潮。野村证券指出，DeepSeek 即将发布的 V4 模型可能通过 mHC 和 Engram 技术降低训练和 | [Link](https://longbridge.com/zh-CN/news/276087180.md) |
| 美股异动速递：科技股强势反弹，Opendoor 涨超 20%，巴克莱银行涨 13% | 美股近一小时市场概况整体市场呈现出明显的分化，科技股和金融股的表现尤为突出。Opendoor Tech 的强劲上涨引领了小盘股的热潮，涨幅达到 20.43%，吸引了大量短线资金的关注。与此同时，巴克莱银行和 FiscalNote 也表现不俗 | [Link](https://longbridge.com/zh-CN/news/276402241.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。